Vijaya R Bhatt
University of Nebraska
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vijaya R Bhatt as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:27 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03932643 · ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell TransplantUniversity of Nebraska · completed · Acute Myeloid Leukemia, Myelodysplastic Syndromes · principal investigator
- Ph2NCT03226418 · Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaUniversity of Nebraska · completed · Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Aging trajectories and outcomes of older adults with acute myeloid leukemiaR37CA276928 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · fiscal years 2023 to 2026 · $515,428 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Amy M Overby · fiscal years 1985 to 2026Named on NCT03226418
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:27 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.Blood Adv · 2018112 citationsRCR 4.1
- Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States.Blood Adv · 201846 citationsRCR 1.7
- Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.J Geriatr Oncol · 202223 citationsRCR 1.7
- A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.J Clin Oncol · 202416 citationsRCR 2.7
- Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.Biol Blood Marrow Transplant · 201915 citationsRCR 0.8
- Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.J Geriatr Oncol · 202411 citationsRCR 1.7
- Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial.Biol Blood Marrow Transplant · 202010 citationsRCR 0.6
- A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.Blood Adv · 20259 citationsRCR 2.3
- A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.Am J Hematol · 20258 citationsRCR 2.3
- A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.Blood Cancer J · 20216 citationsRCR 0.4